The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Key takeaways of Q3FY22 quarter & conference call highlights
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Subscribe To Our Newsletter & Stay Updated
